Related Experiment Videos
Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin
J A Etchason1, T D Miller, R W Squires
1Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905.
Mayo Clinic Proceedings
|January 1, 1991
Summary
Time-release niacin, even at low doses, can cause hepatitis. Symptoms appeared quickly in most patients, differing from high-dose crystalline niacin effects. This highlights potential risks for physicians prescribing niacin for hyperlipidemia.
Area of Science:
- Hepatology
- Pharmacology
- Internal Medicine
Background:
- Niacin (vitamin B3) is commonly prescribed for hyperlipidemia.
- Time-release niacin formulations are widely used.
- Previous reports linked crystalline niacin to hepatotoxicity at high doses and prolonged use.
Observation:
- Hepatitis developed in five patients using low-dose (≤3 g/day) time-release niacin.
- Hepatotoxicity manifested rapidly, within 2 days to 7 weeks, in four patients.
- This contrasts with prior observations of crystalline niacin-induced liver injury.
Findings:
- Low-dose, short-term use of time-release niacin is associated with a distinct pattern of hepatotoxicity.
- Hepatotoxicity can occur even at dosages below 3 g/day.
- The rapid onset of symptoms suggests a different mechanism than crystalline niacin.
Implications:
- Physicians must be aware of potential hepatotoxicity with low-dose, short-term time-release niacin.
- This finding is crucial given the increasing prescription of niacin for hyperlipidemia.
- Monitoring liver function may be warranted even with lower niacin dosages.